Common questions about Лейкостим (FAQ)
Q: Is Лейкостим considered a type of chemotherapy or cancer treatment?
A: According to official product information, Лейкостим is classified as a hematopoietic growth factor, specifically a Granulocyte Colony-Stimulating Factor (G-CSF). Its purpose is to stimulate the bone marrow to produce white blood cells (neutrophils) to fight infection. Official documentation clarifies that this medicine is not a type of cytotoxic chemotherapy.
Q: What are the symptoms of a serious allergic reaction to Лейкостим?
A: Regulatory documents state that serious allergic reactions (anaphylaxis) have been documented with the use of this drug. Symptoms may include swelling of the face, lips, or throat, difficulty breathing, or the development of hives. If these symptoms occur, immediate professional attention should be sought.
Q: Can Лейкостим be taken with over-the-counter pain medications like ibuprofen or paracetamol?
A: Official labeling states there are no known interactions specifically with foods or drinks. For all other medications, including any over-the-counter drugs, official guidance suggests informing their healthcare provider of everything they are taking before starting or continuing therapy.
Q: Does Лейкостим interact with any common vitamins or herbal supplements?
A: The regulatory status regarding interactions with herbal products and supplements is generally unknown, as formal interaction studies have not been performed. Due to this lack of data, patients are advised to inform their healthcare provider of any supplements they may be using.
Q: How long can Лейкостим be kept out of the refrigerator?
A: The drug must be stored in a refrigerator between 2 C and 8 C. If kept at room temperature (typically 9 C to 30 C), the solution is stable for a limited time, such as up to 24 hours. This limited time is defined by the product label and is required for stability.
Q: What is the correct way to dispose of used Лейкостим syringes?
A: Used needles and syringes must be immediately placed into a puncture-proof sharps container. The full sharps container should then be handled and disposed of according to local regulatory and waste management guidelines. This is a regulatory requirement for safe handling and disposal.
Q: Is it possible to become resistant to Лейкостим over time?
A: For patients receiving long-term administration for certain conditions, official documents indicate that the dose may be individually adjusted. This adjustment is based on the patient's measured response to help maintain the required neutrophil count over time.
Q: What is the difference between Лейкостим and pegfilgrastim (single-shot versions)?
A: Both Лейкостим (Filgrastim) and Pegfilgrastim are types of Granulocyte Colony-Stimulating Factor (G-CSF). The primary difference is the duration of effect. Лейкостим is the standard daily-injection formulation, while Pegfilgrastim is a modified, longer-acting version that typically requires fewer injections, often only once per chemotherapy cycle.
Q: Does Лейкостим cause changes to my blood cell counts other than white cells?
A: Yes, regulatory safety information recommends regular monitoring of all blood cell counts, including platelets and red blood cells. The potential for changes means that careful monitoring is required by regulatory guidance, as a low platelet count (thrombocytopenia) is a documented risk.
Q: How quickly does Лейкостим start to raise the white blood cell count?
A: Official studies indicate that a transient increase in neutrophil counts is typically observed within 1 to 2 days after initiating the therapy in patients receiving cytotoxic chemotherapy. Neutrophil recovery is measured over the course of treatment.
Q: What is the maximum length of time a patient is typically given Лейкостим?
A: The duration of therapy is highly dependent on the condition being treated. For chemotherapy-induced neutropenia, it is typically administered for up to two weeks, or until the white blood cell count has recovered to the required level. Other conditions may require long-term, daily administration.
Q: What does a patient need to know about the latex in the prefilled syringe cap?
A: Official labeling notes that the needle cover of the pre-filled syringe may contain dry natural rubber, which is a derivative of latex. This warning is present due to the potential for allergic reactions in individuals with known latex allergy.
Q: Are there any contraindications related to yeast-derived products in Лейкостим?
A: Лейкостим (Filgrastim) is a protein produced in Escherichia coli (a type of bacterium) by recombinant DNA technology. The drug is strictly contraindicated in patients with known hypersensitivity to G-CSFs or any of the inactive ingredients (excipients) in the formulation.
Q: Is Лейкостим used to collect stem cells for a transplant procedure?
A: Yes, Лейкостим is indicated for the mobilisation of peripheral blood progenitor cells (PBPCs). This process uses the drug to help move stem cells from the bone marrow into the bloodstream so they can be collected prior to a stem cell transplant.
Q: What are the possible risks of using Лейкостим if my white blood cell count is already high?
A: Regulatory guidance addresses the risk of the white blood cell count becoming severely high, a condition known as Leukocytosis. If this occurs, the official guidance requires the treatment to be stopped by the healthcare provider to manage this risk.
Q: Can Лейкостим cause inflammation of the aorta?
A: Yes, inflammation of the aorta (Aortitis) has been documented as a rare, serious adverse event. Symptoms that have been documented include fever, abdominal or back pain, and unusual tiredness.
Q: What is Capillary Leak Syndrome and is it a reported risk with Лейкостим?
A: Capillary Leak Syndrome (CLS) is a documented serious risk associated with the drug. CLS is a condition where fluid leaks from the blood vessels. Documented symptoms include generalized swelling, difficulty breathing, or low blood pressure (dizziness).
Q: What types of cancer treatment lead to the use of Лейкостим?
A: Official labeling indicates Лейкостим is used in patients receiving established cytotoxic chemotherapy. This includes regimens used to treat various malignancies such as breast cancer, lymphoma, and small-cell lung cancer, where a drop in white blood cell count is expected.
Q: Does the injection site need to be rotated when using Лейкостим?
A: Yes. The site of the subcutaneous injection is advised to be rotated each time the drug is administered. This rotation is advised as a procedural note in the patient instructions for use.
Q: Is it common to experience fatigue while taking Лейкостим?
A: Yes, regulatory documentation lists fatigue as a common adverse reaction, meaning it is seen in 1 in 100 to < 1 in 10 patients. It is a known potential effect of the treatment.
Q: Can Лейкостим be used by children?
A: Official regulatory documents confirm that the efficacy and safety of Filgrastim are established in children and adolescents. It is approved for use in this population for cancer-related neutropenia and Severe Chronic Neutropenia.
Q: How is the intravenous (IV) solution of Лейкостим prepared?
A: For intravenous use, the drug must be diluted immediately before use. Regulatory instructions require it to be mixed in a 5% glucose (dextrose) solution. It must not be diluted to a final concentration less than 1.5,mu g/mL.
